Folyóiratcikkek tallózása szerző szerint "Török, Szilvia"

A találatok rendezése: Rendezés: Találatok:

  • Anti-diabetic effect of a preparation of vitamins, minerals and trace elements in diabetic rats: a gender difference 
    Sárközy, Márta; Fekete, Veronika; Szűcs, Gergő; Török, Szilvia; Szűcs, Csilla; Barkányi, Judit; Varga, Zoltán; Földesi, Imre; Csonka, Csaba; Kónya, Csaba; Csont, Tamás Bálint; Ferdinandy, Péter (2014)
    BACKGROUND: Although multivitamin products are widely used as dietary supplements to maintain health or as special medical food in certain diseases, the effects of these products were not investigated in diabetes mellitus, ...
  • Cardioprotection by Farnesol: Role of the Mevalonate Pathway 
    Szűcs, Gergő; Murlasits, Zsolt; Török, Szilvia; Kocsis-Fodor, Gabriella; Pálóczi, János; Görbe, Anikó; Csont, Tamás Bálint; Csonka, Csaba; Ferdinandy, Péter (2013)
    Purpose: Farnesol is a key metabolite of the mevalonate pathway and known as an antioxidant. We examined whether farnesol treatment protects the ischemic heart. Methods: Male Wistar rats were treated orally with 0.2, 1, ...
  • Effectiveness of erlotinib treatment in advanced KRAS mutation-negative lung adenocarcinoma patients: Results of a multicenter observational cohort study (MOTIVATE) 
    Sárosi, Veronika; Losonczy, György; Francovszky E; Tolnay E; Török, Szilvia; Gálffy, Gabriella; Hegedűs, Balázs; Döme, Balázs; Ostoros, Gyula (2014)
    OBJECTIVES: Erlotinib is an epidermal growth factor receptor tyrosine-kinase inhibitor (EGFR-TKI), used for the treatment of non-small cell lung cancer. As the clinical significance of KRAS mutational status has not yet ...
  • Fibroblast growth factor receptor inhibition is active against mesothelioma and synergizes with radio- and chemotherapy 
    Schelch K; Hoda MA; Klikovits T; Munzker J; Ghanim B; Wagner C; Garay, Tamás; Laszlo, Viktoria; Setinek U; Döme, Balázs; Filipits M; Pirker C; Heffeter P; Selzer E; Tóvári, József; Török, Szilvia; Kenessey, István; Holzmann K; Grasl-Kraupp B; Marian B; Klepetko W; Berger W; Hegedűs, Balázs; Grusch M (2014)
    RATIONALE: Malignant pleural mesothelioma is an aggressive malignancy characterized by frequent resistance to chemo- and radiotherapy, poor outcome, and limited therapeutic options. Fibroblast growth factors (FGFs) and ...
  • JDP2 overexpression provokes cardiac dysfunction in mice 
    Heger J; Bornbaum J; Wurfel A; Hill C; Brockmann N; Gáspár, Renáta; Pálóczi, János; Varga, Zoltán; Sárközy, Márta; Bencsik, Péter; Csont, Tamás Bálint; Török, Szilvia; Kojonazarov B; Schermuly RT; Bongler K; Parahuleva M; Ferdinandy, Péter; Schulz R; Euler G (2018)
    The transcriptional regulator JDP2 (Jun dimerization protein 2) has been identified as a prognostic marker for patients to develop heart failure after myocardial infarction. We now performed in vivo studies on JDP2-overexpressing ...
  • Localization of sunitinib, its metabolites and its target receptors in tumour bearing mice: a MALDI mass spectrometry imaging study 
    Török, Szilvia; Vegvari A; Rezeli M; Fehniger TE; Tóvári, József; Paku, Sándor; Laszlo, Viktoria; Hegedűs, Balázs; Rózsás, Anita; Döme, Balázs; Marko-Varga G (2015)
    BACKGROUND AND PURPOSE: The clinical impact of antiangiogenic agents remains controversial. Therefore, elucidating the pharmacological properties of these compounds is a pivotal issue. EXPERIMENTAL APPROACH: In our study, ...